Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia

Neuropsychopharmacology

Volumn 40, Issue 9, 2015, Pages 2157-2164

  Chiappelli, Joshua ^a   Rowland, Laura M ^a   Wijtenburg, S Andrea ^a   Muellerklein, Florian ^a   Tagamets, Malle ^a   McMahon, Robert P ^a   Gaston, Frank ^a   Kochunov, Peter ^a   Hong, L Elliot ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MARYLAND TRAIT AND STATE DEPRESSION SCALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGICAL RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; CASE CONTROL STUDY; CINGULATE GYRUS; COMPLICATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; DEPRESSION; FEMALE; GYRUS CINGULI; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84937162788     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.57     Document Type: Article

References (59)

1. Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve RR (1978). Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 13: 65-72.
2. Bermanzohn PC, Porto L, Arlow PB, Pollack S, Stronger R, Siris SG (2000). Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes. Schizophr Bull 26: 517-525.
3. Brand A, Richter-Landsberg C, Leibfritz D (1993). Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15: 289-298.
4. Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009). Psychiatric comorbidities and schizophrenia. Schizophr Bull 35: 383-402.
5. Carter CS, MacDonald AW 3rd, Ross LL, Stenger VA (2001). Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study. Am J Psychiatry 158: 1423-1428.
6. Chang L, Ernst T, Poland RE, Jenden DJ (1996). In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 58: 2049-2056.
7. Chang L, Jiang C, Cunningham E, Buchthal S, Douet V, Andres M et al (2014). Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits. Neurology 82: 2213-2222.
8. Chen LP, Dai HY, Dai ZZ, Xu CT, Wu RH (2014). Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study. Psychiatry Clin Neurosci 68: 357-364.
9. Chiappelli J, Kochunov P, DeRiso K, Thangavelu K, Sampath H, Muellerklein F et al (2014a). Testing trait depression as a potential clinical domain in schizophrenia. Schizophr Res 159: 243-248.
10. Chiappelli J, Nugent KL, Thangavelu K, Searcy K, Hong LE (2014b). Assessment of trait and state aspects of depression in schizophrenia. Schizophr Bull 40: 132-142.
11. Ciccarelli O, Thomas DL, De Vita E, Wheeler-Kingshott CA, Kachramanoglou C, Kapoor R et al (2013). Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol 74: 301-305.
12. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ (2007). The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 90: 186-197.
13. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS (2005). Decreased prefrontal Myo-inositol in major depressive disorder. Biol Psychiatry 57: 1526-1534.
14. Czéh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M et al (2001). Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98: 12796-12801.
15. Edgar N, Sibille E (2012). A putative functional role for oligodendrocytes in mood regulation. Transl Psychiatry 2: e109.
16. Ende G, Braus DF, Walter S, Weber-Fahr W, Henn FA (2000). The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Arch Gen Psychiatry 57: 937-943.
17. Fisher SK, Novak JE, Agranoff BW (2002). Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 82: 736-754.
18. Fornito A, Yucel M, Dean B, Wood SJ, Pantelis C (2009). Anatomical abnormalities of the anterior cingulated cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull 35: 973-993.
19. Frey R, Metzler D, Fischer P, Heiden A, Scharfetter J, Moser E et al (1998). Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 32: 411-420.
20. Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG et al (2006). Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med 55: 1219-1226.
21. Griffin JL, Bollard M, Nicholson JK, Bhakoo K (2002). Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed 15: 375-384.
22. Hamidi M, Drevets WC, Price JL (2004). Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 55: 563-569.
23. Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK (1997). Suicide and schizophrenia: a nationwide psychological autopsy study on age-and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 154: 1235-1242.
24. Kim H, McGrath BM, Silverstone PH (2005). A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol 20: 309-326.
25. Kirov II, Tal A, Babb JS, Herbert J, Gonen O (2013). Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology 80: 39-4.
26. Kochunov P, Hong LE (2014). Neurodevelopmental and neurode-generative models of schizophrenia: white matter at the center stage. Schizophr Bull 40: 721-728.
27. Levine J (1997). Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 7: 147-155.
28. Levine J, Goldberger I, Rapaport A, Schwartz M, Schield C, Elizur A et al (1994). CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia. Eur Neuropsychopharmacol 4: 487-490.
29. Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA et al (2000). Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 48: 861-873.
30. Miguel-Hidalgo JJ, Overholser JC, Jurjus GJ, Meltzer HY, Dieter L, Konick L et al (2011). Vascular and extravascular immunoreactivity for intercellular adhesion molecule 1 in the orbitofrontal cortex of subjects with major depression: age-dependent changes. J Affect Disord 132: 422-431.
31. Miguel-Hidalgo JJ, Wilson BA, Hussain S, Meshram A, Rajkowska G, Stockmeier CA (2014). Reduced connexin 43 immunolabeling in the orbitofrontal cortex in alcohol dependence and depression. J Psychiatr Res 55: 101-109.
32. O'brien RM (2007). A caution regarding rules of thumb for variance inflation factors. Quality Quantity 41: 673-690.
33. Ongür D, Drevets WC, Price JL (1998). Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95: 13290-13295.
34. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
35. Phillips ML, Drevets WC, Rauch SL, Lane R (2003). Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 54: 515-528.
36. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
37. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C (2002). Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 57: 127-138.
38. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS et al (2010). Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68: 625-633.
39. Reyngoudt H, Claeys T, Vlerick L, Verleden S, Acou M, Deblaere K et al (2012). Age-related differences in metabolites in the posterior cingulate cortex and hippocampus of normal ageing brain: a 1H-MRS study. Eur J Radiol 81: e223-e231.
40. Sacher J, Neumann J, Fünfstück T, Soliman A, Villringer A, Schroeter ML (2012). Mapping the depressed brain: a metaanalysis of structural and functional alterations in major depressive disorder. J Affect Disord 140: 142-148.
41. Sands JR, Harrow M (1999). Depression during the longitudinal course of schizophrenia. Schizophr Bull 25: 157-171.
42. Schwerk A, Alves FD, Pouwels PJ, van Amelsvoort T (2014). Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies. JNeurochem 128: 1-87.
43. Shapiro J, Belmaker RH, Biegon A, Seker A, Agam G (2000). Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients. J Neural Transm 107: 603-607.
44. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE (1997). Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 154: 1148-1150.
45. Shimon H, Sobolev Y, Davidson M, Haroutunian V, Belmaker RH, Agam G (1998). Inositol levels are decreased in postmortem brain of schizophrenic patients. Biol Psychiatry 44: 428-432.
46. Silverstone PH, McGrath BM, Kim H (2005). Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 7: 1-10.
47. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA (2004). Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 129: 141-147.
48. Siris SG (2000). Depression in schizophrenia: perspective in the era of 'Atypical' antipsychotic agents. Am J Psychiatry 157: 1379-1389.
49. Soher BJ, Young K, Bernstein A, Aygula Z, Maudsley AA (2007). GAVA: spectral simulation for in vivo MRS applications. J Magn Reson 185: 291-299.
50. Sonawalla SB, Renshaw PF, Moore CM, Alpert JE, Nierenberg AA, Rosenbaum JF et al (1999). Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry 156: 1638-1640.
51. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B (2004). Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 161: 882-888.
52. Strange K (1992). Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 3: 12-27.
53. Uldry M, Steiner P, Zurich MG, Béguin P, Hirling H, Dolci W et al (2004). Regulated exocytosis of an H+/myo-inositol symporter at synapses and growth cones. EMBO J 23: 531-540.
54. Urenjak J, Williams SR, Gadian DG, Noble M (1993). Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981-989.
55. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L et al (2011). Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry 68: 871-880.
56. Wijtenburg SA, Knight-Scott J (2011). Very short echo time improves the precision of glutamate detection at 3T in 1H magnetic resonance spectroscopy. J Magn Reson Imaging 34: 645-652.
57. Wijtenburg SA, Gaston FE, Spieker EA, Korenic SA, Kochunov P, Hong LE et al (2014). Reproducibility of phase rotation STEAM at 3T: focus on glutathione. Magn Reson Med 72: 603-609.
58. Williams RS, Cheng L, Mudge AW, Harwood AJ (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
59. Zheng H, Zhang L, Li L, Liu P, Gao J, Liu X et al (2010). High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 34: 1189-1195.